Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?

AIDS

Volumn 22, Issue 8, 2008, Pages 989-990

  Scott, C ^a   Grover, D ^a   Nelson, M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETRAVIRINE; PLACEBO; RNA DIRECTED DNA POLYMERASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; DRUG INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; VIRUS MUTATION;

ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 43249131402     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282fa75df     Document Type: Article

References (6)

1. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, et al. Writing Committee, British HIV Association. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503.
2. van Leth F, Hassink E, Phanuphak P, Miller S, Gazzard B, Cahn P et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine [Abstract 176]. In: 10th Conference on Retroviruses and Opportunistic Infections; 10-14 February 2003; Boston.
3. Joly V, Yeni P. Nonnucleoside reverse transcriptase inhibitors. Ann Med Interne (Paris) 2000; 151:260-267; Review.
4. Lazzarin A, Campbell T, Clotet B, Johnson TP, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
5. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
6. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14:125-130.